Every 10-Q that Acumen Pharmaceuticals, Inc. (ABOS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABOS filings page.
Acumen Pharmaceuticals, Inc. reported a net loss of $78.8 million for the nine months ended September 30, 2026, compared with $96.2 million a year earlier. Research and development expense was $65.4 million, down from $84.4 million, primarily reflecting lower ALTITUDE-AD manufacturing and contract research costs; higher EBD® license and preclinical costs partly offset the decrease. Operating cash used was $68.9 million versus $96.4 million.
At September 30, cash and marketable securities totaled $78.6 million. Management expects that balance to fund operations into early 2027 and concluded substantial doubt exists about the company’s ability to continue as a going concern. Acumen has no approved products or product-sales revenue. Its Phase 2 ALTITUDE-AD trial is designed for 542 participants, and top-line results are planned for November 2026. In June 2026, Acumen exercised its option to license two EBD® candidates from JCR, paying $9.25 million; JCR may receive up to $555.0 million in development and sales milestones plus single-digit royalties. A private placement of 10,833,331 shares at $3.30 per share closed in March 2026, generating approximately $35.7 million gross before approximately $0.3 million in offering costs.
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech focused on Alzheimer’s disease, advancing its anti-amyloid-beta oligomer antibody sabirnetug in the Phase 2 ALTITUDE-AD trial, with top-line results planned for late 2026. The company also nominated two Enhanced Brain Delivery™ candidates, ACU301 and ACU401, under its JCR collaboration and exercised an option in June 2026, triggering a $9.25 million in‑process R&D payment.
For the six months ended June 30, 2026, Acumen reported a net loss of $53.5 million, improving from $69.7 million in 2025, as research and development expenses fell to $44.3 million from $62.4 million primarily due to lower manufacturing and CRO costs on ALTITUDE-AD. General and administrative expenses were stable at $9.4 million. Cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, helped by a March 2026 private placement raising about $35.7 million gross.
The company carries an accumulated deficit of $499.9 million and continues to incur operating losses. Management states that current cash resources are expected to fund operations into early 2027 but may not cover at least 12 months beyond the financial statement issuance date, leading to a disclosed substantial doubt about its ability to continue as a going concern.
Acumen Pharmaceuticals reported a smaller quarterly loss while highlighting funding risk. For the three months ended March 31, 2026, the company recorded a net loss of $20.7 million, improving from $28.8 million a year earlier, as research and development spending decreased to $16.5 million from $25.3 million with lower manufacturing and CRO costs for its ALTITUDE-AD Phase 2 trial.
General and administrative expenses declined modestly to $4.7 million. Acumen ended the quarter with cash, cash equivalents and marketable securities totaling $128.4 million and completed a private placement of 10,833,331 shares at $3.30 per share for gross proceeds of about $35.7 million. Management expects these resources to fund operations into early 2027 but concluded that substantial doubt exists about its ability to continue as a going concern without additional capital.
Development remains centered on sabirnetug, an Aß oligomer–targeting antibody in the Phase 2 ALTITUDE-AD trial, with top-line results planned for late 2026, alongside a subcutaneous formulation and an Enhanced Brain Delivery (EBD™) program targeting an IND filing around mid‑2027.
Acumen Pharmaceuticals (ABOS) is a clinical-stage company advancing sabirnetug, an oligomer-targeted monoclonal antibody for Alzheimer’s disease. The company completed enrollment in its Phase 2 ALTITUDE-AD trial in March 2025 after initiating dosing in May 2024, and its Phase 1 INTERCEPT-AD topline results met primary and secondary objectives in July 2023. As of June 30, 2025, Acumen held $166.2 million of cash and marketable securities and reported working capital of $123.5 million, which management believes funds operations into early 2027.
Operating results reflect rapidly higher development spending: research and development expense rose to $62.4 million for the six months ended June 30, 2025 (up 95% year-over-year), driving a net loss of $69.7 million for the same period and an accumulated deficit of $394.9 million. The company has a $31.6 million term loan with embedded derivatives and an effective interest rate around 14% for the period. In July 2025 Acumen entered a collaboration with JCR with potential payments and milestones up to $555 million plus royalties.